Novel therapeutic strategy for the inhibition of pseudorabies virus (PRV) infection in C57BL/6 mouse by recombinant nuclease caralytic antibody

Abstract

3D8 scFv is a recombinant monoclonal antibody with nuclease activity originally isolated from autoimmune-prone MRL mice. Previously, we have demonstrated that HeLa cell lines expressing 3D8 scFv conferred resistance to HSV-1 and PRV by nuclease activity of 3D8 scFv. In this study, we show that 3D8 scFv can be delivered to the target tissues and cells by intraperitoneal injection and have a therapeutic effect against PRV. Intraperitoneal injection of 5 µg and 10 µg 3D8 scFv did not develop any noticeable toxicity. C57BL/6 mouse showed 9% survival rate after 10LD50 PRV intramuscular infection. By contrast, 3D8 scFv injected C57BL/6 mouse exhibited 57% (5 µg; group E) and 47% (10 µg; group F) survival rates. This therapeutic effect of 3D8 scFv against PRV was also supported by qRT-PCR, southern hybridization, and immunohistochemistry. Comparative mRNA expression data using several chemokines (iNOS and CXCL10) revealed that the antiviral mechanism on C57BL/6 mice was due to the nuclease activity of 3D8 scFv. Therefore, our results indicated that the nuclease activity of 3D8 scFv can be utilized as an effective antiviral agent on several animal models